Event Date/Time: Oct 22, 2003 End Date/Time: Oct 23, 2003
Report as Spam


The unmet needs in anti-cancer drug development demand that pharmaceutical companies identify the areas that will yield the greatest return on their oncology R&D investments. There are many market-specific issues that must be considered in building a cancer portfolio, including the development of drugs with novel mechanisms and pre-clinical promise, but high-risk profiles; regulatory risk;and the challenge of commercialization in a crowded marketplace. The emergence of targeted cancer therapy and personalized medicine may initially reduce the market size for a drug and challenge the traditional economics of drug development,adding a layer of complexity to pipeline development and management. How do you mange your cancer portfolio to minimize risk in this highly competitive marketplace? You must understand emerging trends in cancer therapeutics and the deal making landscape in order to strategically position your company to capitalize on available-and new-opportunities.

Over the past two years, the Institute for International Research has provided oncology portfolio management solutions to pharmaceutical executives. In its third year, the Building a Balanced Cancer Portfolio conference is designed to provide pharmaceutical and biotech professionals with the latest insights in the framework behind portfolio management, business development,and licensing decisions for cancer therapeutics. This conference addresses the current needs and emerging strategic issues in portfolio planning for oncology drugs and represents the only pharmaceutical portfolio management event specific to cancer therapeutics.

Highlights Include:

Identifying how to use corporate development to create focus in oncology
Demonstrating the discovery and development of Velcade, a novel proteasome inhibitor for cancer therapy
Understanding various aspects of an oncology franchise and the implications to building a balanced cancer portfolio
Addressing questions around commercial expectations of a cancer blockbuster, a blockbuster’s life and oncology’s franchise quotient
Developing an effective oncology organizational structure and considerations to optimize the commercial success of anti-cancer agents
Learning how to keep up with the changing reimbursement environment in oncology and understanding how this can impact the use of specific types of cancer therapies
Realizing how predictive risk management can achieve commercial success with targeted cancer therapies
Reviewing successful oncology licenses and collaborations with the NIH
Managing partnering to propagate a novel oncology pipeline
Building a blockbuster oncology drug from a small company perspective
...and more